Home/NeoGenomics/Michael A. Kelly
MA

Michael A. Kelly

Board Member

NeoGenomics

Therapeutic Areas

NeoGenomics Pipeline

DrugIndicationPhase
RaDaR® STMRD Detection & Recurrence Monitoring (Pan-Cancer)Commercial
PanTracer™ Pro PortfolioComprehensive Genomic Profiling for Therapy SelectionCommercial
HRD TestingHomologous Recombination Deficiency StatusCommercial
Oncology Data SolutionsReal-World Evidence & Biomarker DiscoveryCommercial & Development